Want to see ARCT full AI Analyst Report?
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
ARCT Analyst Ratings
Strong Buy
7Buy2Hold0Sell
Based on 9 analysts giving stock ratings to Arcturus Therapeutics in the past 3 months
ARCT Stock 12 Month Forecast
Average Price Target
$21.29▲(92.98% Upside)Based on 9 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $21.29 with a high forecast of $41.00 and a low forecast of $9.00. The average price target represents a 92.98% change from the last price of $11.03.
Past 12 Months12 Month ForecastJan2026Oct2026
High$41.00
Average$21.29
Low$9.00
Highest Price TargetHighest$41.00Average Price Target$21.29Lowest Price TargetLowest$9.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | Leerink Partners | $13→$19 | buy | 72.26%Upside | Assigned | 10/12/26 | ||
| Unknown AnalystNot Ranked | Wells Fargo | $20 | buy | 81.32%Upside | Reiterated | 10/02/26 | ||
| Thomas Shrader | BTIG | $20 | buy | 81.32%Upside | Reiterated | 10/01/26 | ||
| Yigal Nochomovitz | Citi | $20 | buy | 81.32%Upside | Upgraded | 09/24/26 | ||
| Andrew Fein | H.C. Wainwright | $9 | hold | -18.40%Downside | Reiterated | 09/24/26 | ||
| Whitney Ijem | Canaccord Genuity | $20 | buy | 81.32%Upside | Reiterated | 09/24/26 | ||
| Adam Walsh | Roth MKM | $41 | buy | 271.71%Upside | Reiterated | 09/24/26 | ||
| Myles Minter | William Blair | ― | buy | ― | Reiterated | 09/24/26 | ||
| Seamus Fernandez | Guggenheim | ― | hold | ― | Reiterated | 08/06/26 | ||
| Ilya Zubkov | Freedom Capital Markets | $27 | buy | 144.79%Upside | Initiated | 07/02/26 | ||
| Mayank Mamtani | B. Riley Securities | $22 | buy | 99.46%Upside | Initiated | 03/18/26 | ||
| Yasmeen Rahimi | Piper Sandler | $72→$25 | buy | 126.65%Upside | Reiterated | 03/04/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Unknown AnalystNot Ranked | 10/12/26 | $13→$19 | buy | 72.26%Upside | Assigned | Leerink Partners | ||
| Unknown AnalystNot Ranked | 10/02/26 | $20 | buy | 81.32%Upside | Reiterated | Wells Fargo | ||
| Thomas Shrader | 10/01/26 | $20 | buy | 81.32%Upside | Reiterated | BTIG | ||
| Yigal Nochomovitz | 09/24/26 | $20 | buy | 81.32%Upside | Upgraded | Citi | ||
| Andrew Fein | 09/24/26 | $9 | hold | -18.40%Downside | Reiterated | H.C. Wainwright | ||
| Whitney Ijem | 09/24/26 | $20 | buy | 81.32%Upside | Reiterated | Canaccord Genuity | ||
| Adam Walsh | 09/24/26 | $41 | buy | 271.71%Upside | Reiterated | Roth MKM | ||
| Myles Minter | 09/24/26 | ― | buy | ― | Reiterated | William Blair | ||
| Seamus Fernandez | 08/06/26 | ― | hold | ― | Reiterated | Guggenheim | ||
| Ilya Zubkov | 07/02/26 | $27 | buy | 144.79%Upside | Initiated | Freedom Capital Markets | ||
| Mayank Mamtani | 03/18/26 | $22 | buy | 99.46%Upside | Initiated | B. Riley Securities | ||
| Yasmeen Rahimi | 03/04/26 | $72→$25 | buy | 126.65%Upside | Reiterated | Piper Sandler |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Arcturus Therapeutics
3 Months
Success Rate7/16 ratings generated profit
44%
Average Return
+6.13%
Copying Myles Minter's trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of +6.13% per trade.
1 Year
Success Rate4/11 ratings generated profit
36%
Average Return
-11.46%
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -11.46% per trade.
2 Years
Success Rate6/16 ratings generated profit
38%
Average Return
-2.99%
Copying Myles Minter's trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -2.99% per trade.
ARCT Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 9 | 9 | 5 |
| Buy | 3 | 3 | 7 | 6 | 4 |
| Hold | 2 | 2 | 4 | 4 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 10 | 12 | 20 | 19 | 11 |
In the current month, ARCT has received 9 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the past 3 months is 21.29.
ARCT Financial Forecast
High$-0.29
Consensus$-0.69
Low$-0.92
ARCT Earnings Forecast
Next quarter’s earnings estimate for ARCT is -$0.69 with a range of -$0.92 to -$0.29. The previous quarter’s EPS was -$0.84. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$16M
Consensus$8M
Low$2M
ARCT Sales Forecast
Next quarter’s sales forecast for ARCT is $8.00M with a range of $2.00M to $16.01M. The previous quarter’s sales results were $880.00K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ARCT Stock Forecast FAQ
What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is $21.29.
What is ARCT’s upside potential, based on the analysts’ average price target?
Arcturus Therapeutics has 92.98% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARCT a Buy, Sell or Hold?
Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
What is Arcturus Therapeutics’s price target?
The average price target for Arcturus Therapeutics is $21.29. This is based on 9 12-month price targets, issued in the past 3 months. The highest analyst price target is $41.00, the lowest forecast is $9.00. The average price target represents a 92.98% increase from the current price of $11.03.
What do analysts say about Arcturus Therapeutics?
Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of ARCT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.